UREA CYCLE DEFECTS

Urea Cycle Defects — where hyperammonemia can cause irreversible brain damage within hours, and the specific gene determines protein tolerance, nitrogen scavenger therapy selection, and whether liver transplantation is curative.

Whole genome sequencing evaluates all urea cycle genes — OTC, CPS1, ASS1, ASL, ARG1, NAGS — and distinguishes X-linked OTC deficiency from autosomal recessive defects, enabling accurate genetic counseling and family screening.

OTC
CPS1
ASS1
ASL
ARG1
NAGS

About this condition

Urea Cycle Defects

Urea cycle defects (UCDs) are a group of inherited metabolic disorders caused by deficiency of enzymes or transporters in the urea cycle — the hepatic pathway that converts neurotoxic ammonia to urea for renal excretion. Six primary UCDs are recognized: ornithine transcarbamylase (OTC) deficiency (X-linked, most common, ~50% of all UCDs), carbamoyl phosphate synthetase I (CPS1) deficiency, argininosuccinate synthetase (ASS1) deficiency (citrullinemia type I), argininosuccinate lyase (ASL) deficiency, arginase (ARG1) deficiency, and N-acetylglutamate synthase (NAGS) deficiency. Combined incidence is approximately 1 in 30,000-35,000 births.

UCDs present with hyperammonemia — elevated blood ammonia that is directly neurotoxic. Severe neonatal-onset forms (typically OTC, CPS1, or ASS1 in males with complete enzyme deficiency) present within the first days of life with progressive lethargy, poor feeding, vomiting, hypothermia, and rapid progression to coma and death if untreated. Late-onset forms present with recurrent episodes of hyperammonemia triggered by catabolic stress (illness, surgery, high-protein intake, postpartum period), which can cause encephalopathy, cerebral edema, and progressive cognitive impairment with each episode.

Management includes dietary protein restriction, nitrogen scavenger therapy (sodium benzoate and/or sodium phenylbutyrate/glycerol phenylbutyrate, which provide alternative pathways for nitrogen excretion), essential amino acid supplementation, and emergency hyperammonemia protocols. Liver transplantation is curative for hepatic UCDs (OTC, CPS1, ASS1, NAGS) because the urea cycle is exclusively hepatic — a transplanted liver provides functional enzyme. mRNA therapy delivering functional OTC mRNA to hepatocytes is in clinical trials for OTC deficiency, potentially offering a non-surgical alternative to liver transplantation.

OTC deficiency is X-linked — affected males typically present in the neonatal period, but carrier females can present at any age, often triggered by catabolic stress (illness, surgery, postpartum). Postpartum hyperammonemia in a previously healthy woman should prompt OTC carrier testing.

Gene locus: OTC (Xp11.4), CPS1 (2q34), ASS1 (9q34.11), ASL (7q11.21), ARG1 (6q23.2), NAGS (17q21.31)

OTC deficiency is X-linked; other UCDs are autosomal recessive. The inheritance pattern has profound implications for family screening, prenatal diagnosis, and recurrence risk — only molecular diagnosis reliably determines the specific UCD.

Hyperammonemia kills neurons in hours — emergency protocols require knowing the specific UCD for optimal management

Each UCD has a specific biochemical profile that determines the optimal emergency management. ASS1 deficiency (citrullinemia) accumulates citrulline — arginine supplementation is critical. ASL deficiency accumulates argininosuccinic acid — arginine provides both a nitrogen sink and a metabolic substrate. OTC and CPS1 have elevated glutamine rather than citrulline. Nitrogen scavenger selection, dialysis thresholds, and nutritional management all vary by UCD subtype. Molecular diagnosis before the first hyperammonemic crisis enables creation of a gene-specific emergency protocol that reduces brain damage during subsequent episodes.

mRNA therapy for OTC deficiency in clinical trials — molecular confirmation required, and early enrollment maximizes benefit before cumulative brain injury

mRNA therapy delivering functional OTC mRNA via lipid nanoparticles to hepatocytes is in advanced clinical development. This approach could provide OTC enzyme activity without liver transplantation — avoiding the surgical risk, lifelong immunosuppression, and limited organ availability of transplantation. Trial enrollment requires confirmed OTC molecular diagnosis. Early enrollment — before repeated hyperammonemic crises have caused cumulative neurological injury — maximizes the potential cognitive benefit of restoring OTC activity.

Urea Cycle Defects — where hyperammonemia can cause irreversible brain damage within hours, and the specific gene determines protein tolerance, nitrogen scavenger therapy selection, and whether liver transplantation is curative.

Urea Cycle Defects

OTC deficiency is X-linked; other UCDs are autosomal recessive. The inheritance pattern has profound implications for family screening, prenatal diagnosis, and recurrence risk — only molecular diagnosis reliably determines the specific UCD.

Hyperammonemia kills neurons in hours — emergency protocols require knowing the specific UCD for optimal management

mRNA therapy for OTC deficiency in clinical trials — molecular confirmation required, and early enrollment maximizes benefit before cumulative brain injury

Others in Metabolic

One test. A lifetime of answers.